Last reviewed · How we verify
Amoxicillin-Metronidazole Bismuth quadruple therapy
At a glance
| Generic name | Amoxicillin-Metronidazole Bismuth quadruple therapy |
|---|---|
| Also known as | Proton pump inhibitor, Rabeprazole, Pariet®, Antibiotics, Amoxicillin, Amoxicillin®, Antibiotics, Metronidazole, Flagyl®, Colloidal Bismuth, Tripotassium dicitrate bismuthate, KCB® |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (NA)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: